Disc Medicine

Q2 FY2026 EarningsQ2 FY2026 results outperformed consensus estimates on the bottom line, with a GAAP net loss of $59.5M vs. an expected $66.7M, and EPS of -$1.54 vs. the -$1.73 consensus. While the company remains in a pre-revenue clinical stage, total operating expenses of $65.1M were lower than the implied EBIT loss of $70.1M. The cash position of $717.7M provides a significant runway into 2029, and major pipeline catalysts remain on track, specifically the Phase 3 APOLLO topline data expected in Q4 2026.